The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis

The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis

Abstract The development of granulomas with central necrosis harboring Mycobacterium tuberculosis (Mtb) is the hallmark of human tuberculosis (TB). New anti-TB therapies need to effectively penetrate the cellular and necrotic compartments of these lesions and reach sufficient concentrations to elimi...

Full description

Saved in:
Bibliographic Details
Main Authors: Andreas Römpp, Axel Treu, Julia Kokesch-Himmelreich, Franziska Marwitz, Julia Dreisbach, Nadine Aboutara, Doris Hillemann, Moritz Garrelts, Paul J. Converse, Sandeep Tyagi, Sina Gerbach, Luzia Gyr, Ann-Kathrin Lemm, Johanna Volz, Alexandra Hölscher, Leon Gröschel, Eva-Maria Stemp, Norbert Heinrich, Florian Kloss, Eric L. Nuermberger, Dominik Schwudke, Michael Hoelscher, Christoph Hölscher, Kerstin Walter
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-56146-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-56146-9

Similar Items